MicroRNA and drug resistance

Cancer Gene Therapy

Volumn 17, Issue 8, 2010, Pages 523-531

  Ma, J ^a   Dong, C ^a   Ji, C ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Cancer; Drug resistance; MicroRNA; Review

Indexed keywords

ANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FULVESTRANT; GEMCITABINE; HYDROXYUREA; MICRORNA; MITOXANTRONE; NOGALAMYCIN; NOGAMYCIN; NSC 265450; NSC 670550; PACLITAXEL; PLUMBAGIN; RECOMBINANT GAMMA INTERFERON; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TAMOXIFEN; TOPOTECAN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

3' UNTRANSLATED REGION; APOPTOSIS; BILE DUCT CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DRUG SENSITIVITY; GENE EXPRESSION; GENE THERAPY; HUMAN; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; MICROARRAY ANALYSIS; NEUROBLASTOMA; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; BIOSYNTHESIS; DRUG RESISTANCE; GENETICS; NEOPLASMS;

DRUG RESISTANCE, NEOPLASM; HUMANS; MICRORNAS; NEOPLASMS;

EID: 77954818666     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.18     Document Type: Review

References (74)

1. Bartel DP. MiRNAs: genomics, biogenesis, mechanism and function. Cell 2004; 116: 281-297.
2. Carrington JC, Ambros V. Role of microRNAs in plant and animal development. Science 2003; 301: 336-338.
3. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001; 294: 853-858.
4. Perera RJ, Ray A. MicroRNAs in the search for understanding human diseases. Biodrugs 2007; 21: 97-104.
5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
6. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-355.
7. Lytle JR, Yario TA, Steitz JA. Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5 UTR as in the 3 UTR. Proc Natl Acad Sci USA 2007; 104: 9667-9672.
8. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318: 1931-1934.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
10. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-688.
11. Burchenal JH, Robinson E, Johnston SF, Kushida MH. The induction of resistance to 4-amino-N10-methylpteroylgluta-mic acid in a strain of transmitted mouse leukemia. Science 1950; 111: 116.
12. Climent J, Dimitrow P, Fridlyand J, Palacios J, Siebert R, Albertson DG et al. Deletion of chromosome 11q predicts response to anthracycline-based chemotherapy in early breast cancer. Cancer Res 2007; 67: 818-826.
13. Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z et al. MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol Cancer Ther 2007; 6: 1483-1491.
14. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283: 29897-29903.
15. Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A et al. Regulation of the p27(kip1) tumor suppressor by miR-221and miR-222 promotes cancer cell proliferation. EMBO J 2007; 26: 3699-3708.
16. Xin F, Li M, Balch C, Thomson M, Fan M, Liu Y et al. Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 2009; 25: 430-434.
17. Benson JR. Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol 2004; 5: 229-239.
18. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005; 11: 937s-943s.
19. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66: 11954-11966.
20. Giacinti L, Claudio PP, Lopez M, Giordano A. Epigenetic information and estrogen receptor alpha expression in breast cancer. Oncologist 2006; 11: 1-8.
21. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem 2008; 283: 31079-31086.
22. Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endo-crinol 2007; 21: 1132-1147.
23. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007; 26: 2799-2803.
24. Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, Garman KS et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One 2008; 3: e1908.
25. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF et al. Involvement of micro-RNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-2159.
26. Chen YN, Mickley LA, Schwartz AM, Acton EM, Hwang JL, Fojo AT. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein. J Biol Chem 1990; 265: 10073-10080.
27. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-15670.
28. Chen GQ, Zhao ZW, Zhou HY, Liu YJ, Yang HJ. Systematic analysis of microRNA involved in resistance of the MCF-7 human breast cancer cell to doxorubicin. Med Oncol 2 May 2009; [Epub ahead of print].
29. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 2009; 75: 1374-1379.
30. Al-Hajj M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 2007; 19: 61-64.
31. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-1123.
32. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-433.
33. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008; 68: 10307-10314.
34. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 2008; 111: 478-486.
35. Paulus P, Stanley ER, Schafer R, Abraham D, Aharinejad S. Colony-stimulating factor-1 antibody reverses chemoresis-tance in human MCF-7 breast cancer xenografts. Cancer Res 2006; 66: 4349-4356.
36. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG et al. Role of microRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008; 76: 582-588.
37. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008; 7: 1-9.
38. Schaefer U, Voloshanenko O, Willen D, Walczak H. TRAIL: a multifunctional cytokine. Front Biosci 2007; 12: 3813-3824.
39. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007; 39: 1462-1475.
40. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008; 27: 3845-3855.
41. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F et al. MiRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005; 102: 18081-18086.
42. He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S et al. The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 2005; 102: 19075-19080.
43. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 2006; 108: 3068-3071.
44. Fujita Y, Kojima K, Hamada N, Ohhashi R, Akao Y, Nozawa Y et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 2008; 377: 114-119.
45. Kojima K, Ohhashi R, Fujita Y, Hamada N, Akao Y, Nozawa Y et al. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun 2008; 373: 423-428.
46. Chu F, Chou PM, Zheng X, Mirkin BL, Rebbaa A. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 2005; 65: 10183-10187.
47. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105: 13421-13426.
48. Johnson DG, Ohtani K, Nevins JR. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994; 8: 1514-1525.
49. Wang C, Chen L, Hou X, Li Z, Kabra N, Ma Y et al. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol 2006; 8: 1025-1031.
50. Tong AW, Fulgham P, Jay C, Chen P, Khalil I, Liu S et al. MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther 2009; 16: 206-216.
51. Fan D, Zhang X, Chen X, Mou Z, Hu J, Zhou S et al. Bird's-eye view on gastric cancer research of the past 25 years. J Gastroenterol Hepatol 2005; 20: 360-365.
52. Xia L, Zhang D, Du R, Pan Y, Zhao L et al. miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int J Cancer 2008; 123: 372-379.
53. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 7: 541-546.
54. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26: 745-752.
55. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007; 17: 1298-1307.
56. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007; 67: 8433-8438.
57. Ji Q, Hao X, Meng Y, Zhang M, Desano J, Fan D et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008; 8: 266.
58. To KK, Zhan Z, Litman T, Bates SE. Regulation of ABCG2 expression at the 3 untranslated region of its mRNA through modulation of transcript Ssability and protein translation by a putative microRNA in the S1 colon cancer cell line. Mol Cell Biol 2008; 28: 5147-5161.
59. Liao R, Sun J, Zhang L, Lou G, Chen M, Zhou D et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J Cell Biochem 2008; 104: 805-817.
60. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K et al. Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 2006; 3: 317-324.
61. Tsang WP, Kwok TT. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 2008; 13: 1215-1222.
62. Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001; 97: 483-489.
63. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41: 2502-2512.
64. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The microRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 2007; 282: 8256-8264.
65. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangio-carcinoma cell lines. Gastroenterology 2006; 130: 2113-2129.
66. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004; 64: 3517-3524.
67. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133-6140.
68. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23: 4051-4060.
69. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008; 3: e2236.
70. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 Gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
71. Zenz T, Mohr J, Eldering E, Kater AP, Buhler A, Kienle D et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009; 113: 3801-3808.
72. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801.
73. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
74. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-13949.